Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bavdegalutamide - Arvinas

Next Previous
Drug Profile

Bavdegalutamide - Arvinas

Alternative Names: ARV-110

Latest Information Update: 12 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Yale University
  • Developer Arvinas
  • Class Amides; Antineoplastics; Chlorobenzenes; Cyclohexanes; Fluorobenzenes; Isoindoles; Phenyl ethers; Piperazines; Piperidines; Pyridazines; Small molecules
  • Mechanism of Action Androgen receptor degradation enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Prostate cancer

Most Recent Events

  • 10 Apr 2025 Arvinas completes the phase I trial in Prostate cancer (Combination therapy, Hormone refractory, Metastatic disease, Second-line therapy or greater) in USA, Canada, United Kingdom, France (PO) (NCT05177042)
  • 28 Mar 2025 No recent reports of development identified for phase-I development in Prostate-cancer(Combination therapy, Hormone refractory, Metastatic disease, Second-line therapy or greater) in Canada (PO, Tablet)
  • 28 Mar 2025 No recent reports of development identified for phase-I development in Prostate-cancer(Combination therapy, Hormone refractory, Metastatic disease, Second-line therapy or greater) in USA (PO, Tablet)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top